Maligne Erkrankungen der Haut

• Literatur von Mitarbeitern der Universitäts-Hautklinik

• 1 Hauschild A, Garbe C. Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma?. Nat Rev Clin Oncol 2015; 12: 439-440
• 2 Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
• 3 Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888
• 4 Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918
• 5 Romano E, Kusio-Kobialka M, Foukas PG et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 2015; 112: 6140-6145
• 6 Ulmer A, Dietz K, Hodak I et al. Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 2014; 11
• 7 Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207-211
• 8 Brantsch KD, Meisner C, Schönfisch B et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720
• 9 Braumüller H, Wieder T, Brenner E et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494: 361-365
• 10 Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526